nach oben

Erschienen in:

01.04.2013 | Original Article

Repeated radioimmunotherapy with ¹³¹I-rituximab for patients with low-grade and aggressive relapsed or refractory B cell non-Hodgkin lymphoma

verfasst von: Hye Jin Kang, Seung-Sook Lee, Byung Hyun Byun, Kyeong Min Kim, Ilhan Lim, Chang Woon Choi, Cheolwon Suh, Won Seog Kim, Seung-Hyun Nam, Soon Il Lee, Hyeon Seok Eom, Dong-Yeop Shin, Sang Moo Lim

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

A single treatment of ¹³¹I-rituximab in patients with B cell non-Hodgkin lymphoma (NHL) showed a modest rate of response (29 %) in a relatively short duration (median 2.9 months). On the basis of this result, we investigated whether repeated treatment with ¹³¹I-rituximab could improve the response.

Patients and methods

Thirty-one patients with relapsed or refractory B cell NHL received unlabeled rituximab (70 mg) immediately prior to the administration of a therapeutic dose of ¹³¹I-rituximab. The tumor response was evaluated 1 month later by contrast-enhanced ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography. Radioimmunotherapy (RIT) was repeated at 4-week intervals.

Results

A total of 87 cycles of RIT were administered. Repeated RIT yielded twofold increases in response rate (68 %) and in median response duration (8.6 months). This protocol also induced a favorable response in patients with an aggressive histology compared to that induced by a single treatment (50 vs. 9 %, respectively, p = 0.063). The toxicities were principally hematologic with grade 4 thrombocytopenia occurring in 12 % and neutropenia occurring in 17 % of the 85 assessable cycles.

Conclusions

Compared to a single treatment, repeated RIT with ¹³¹I-rituximab increased the response rate and duration for patients with relapsed or refractory B cell NHL, including those with an aggressive histology.

Nur mit Berechtigung zugänglich

Kaminski MS, Zelenetz AD, Press OW, Saleh M, Leonard J, Fehrenbacher L, Lister TA, Stagg RJ, Tidmarsh GF, Kroll S, Wahl RL, Knox SJ, Vose JM (2001) Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol 19(19):3918–3928PubMed

Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-Lopez AJ, Multani P, White CA (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 20(10):2453–2463PubMedCrossRef

Leahy MF, Seymour JF, Hicks RJ, Turner JH (2006) Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin’s lymphoma. J Clin Oncol 24(27):4418–4425PubMedCrossRef

Kang HJ, Lee SS, Kim KM, Choi TH, Cheon GJ, Kim WS, Suh C, Yang SH, Lim SM (2011) Radioimmunotherapy with (131)I-rituximab for patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma (NHL). Asia Pac J Clin Oncol 7(2):136–145PubMedCrossRef

Stabin MG (1996) MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 37(3):538–546PubMed

Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI sponsored international working group. J Clin Oncol 17(4):1244PubMed

Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, LaCasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen LJ, Tsien C, Vose JM, Wierda WG, Yahalom J, Zafar N (2011) Non-Hodgkin’s lymphomas. J Natl Compr Canc Netw 9(5):484–560PubMed

Schaefer NG, Huang P, Buchanan JW, Wahl RL (2011) Radioimmunotherapy in non-Hodgkin lymphoma: opinions of nuclear medicine physicians and radiation oncologists. J Nucl Med 52(5):830–838PubMedCrossRef

Schaefer NG, Ma J, Huang P, Buchanan J, Wahl RL (2010) Radioimmunotherapy in non-Hodgkin lymphoma: opinions of U.S. medical oncologists and hematologists. J Nucl Med 51(6):987–994PubMedCrossRef

10.

Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, Glenn S, Butchko G, Fisher D, Porter B et al (1993) Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 329(17):1219–1224PubMedCrossRef

11.

Gopal AK, Gooley TA, Maloney DG, Petersdorf SH, Eary JF, Rajendran JG, Bush SA, Durack LD, Golden J, Martin PJ, Matthews DC, Appelbaum FR, Bernstein ID, Press OW (2003) High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood 102(7):2351–2357PubMedCrossRef

12.

Nademanee A, Forman S, Molina A, Fung H, Smith D, Dagis A, Kwok C, Yamauchi D, Anderson AL, Falk P, Krishnan A, Kirschbaum M, Kogut N, Nakamura R, O’Donnell M, Parker P, Popplewell L, Pullarkat V, Rodriguez R, Sahebi F, Smith E, Snyder D, Stein A, Spielberger R, Zain J, White C, Raubitschek A (2005) A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 106(8):2896–2902PubMedCrossRef

13.

DeNardo GL, Schlom J, Buchsbaum DJ, Meredith RF, O’Donoghue JA, Sgouros G, Humm JL, DeNardo SJ (2002) Rationales, evidence, and design considerations for fractionated radioimmunotherapy. Cancer 94(4 Suppl):1332–1348PubMedCrossRef

14.

DeNardo GL, DeNardo SJ, Lamborn KR, Goldstein DS, Levy NB, Lewis JP, O’Grady LF, Raventos A, Kroger LA, Macey DJ, McGahan JP, Mills SL, Shen S (1998) Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody. Cancer Biother Radiopharm 13(4):239–254PubMedCrossRef

15.

DeNardo GL, DeNardo SJ, Goldstein DS, Kroger LA, Lamborn KR, Levy NB, McGahan JP, Salako Q, Shen S, Lewis JP (1998) Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin’s lymphoma. J Clin Oncol 16(10):3246–3256PubMed

16.

Richman CM, DeNardo SJ, O’Grady LF, DeNardo GL (1995) Radioimmunotherapy for breast cancer using escalating fractionated doses of 131I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions. Cancer Res 55(23 Suppl):5916s–5920sPubMed

Titel: Repeated radioimmunotherapy with 131I-rituximab for patients with low-grade and aggressive relapsed or refractory B cell non-Hodgkin lymphoma
verfasst von: Hye Jin Kang
Seung-Sook Lee
Byung Hyun Byun
Kyeong Min Kim
Ilhan Lim
Chang Woon Choi
Cheolwon Suh
Won Seog Kim
Seung-Hyun Nam
Soon Il Lee
Hyeon Seok Eom
Dong-Yeop Shin
Sang Moo Lim
Publikationsdatum: 01.04.2013
Verlag: Springer-Verlag
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 4/2013
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-013-2087-z

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Repeated radioimmunotherapy with ¹³¹I-rituximab for patients with low-grade and aggressive relapsed or refractory B cell non-Hodgkin lymphoma